News

The difficulty in spotting minute amounts of disease circulating in the bloodstream has proven a stumbling block in the detection and treatment of cancers that advance stealthily with few symptoms. With a novel electrochemical biosensing device that identifies the tiniest signals these biomarkers emit, NJIT researchers are hoping to bridge this gap.

Scientists have developed a new method that greatly simplifies the production of large DNA molecules containing many hundreds of genes. With this method, they have built the first genome of a bacterium entirely designed by a computer algorithm. The method has the potential to revolutionise biotechnology.

HIV-positive people treated with antiretroviral therapy who had high levels of autoantibodies also had increased levels of Staphylococcus aureus products in their blood, raising new possibilities of a "leaky gut" mechanism in HIV pathology.

By capturing more cancer cells than blood draw screening, this device could help doctors understand a tumor’s biology and make decisions about treatment.

Victoria University of Wellington scientists developing ground-breaking new vaccines to treat drug addiction have received one of fifteen $150,000 Explorer Grants from the Health Research Council of New Zealand.

The human immune response to infection with dengue (a close "cousin" of the Zika virus) has been teased out and may provide guidance to those formulating vaccines.

Academic experts in Natural Language Processing from Lancaster University who are interested in deception have compared the language used within written April Fools hoaxes and fake news stories.

Using supercomputers, scientists are designing proteins that self-assemble to combine and resemble life-giving molecules like hemoglobin. The scientists say their methods could be applied to useful technologies such as pharmaceutical targeting and artificial energy harvesting. Using jellyfish proteins, the scientists were able to assemble a complex sixteen protein structure composed of two stacked octamers.

Medicine has great hopes for personalized cancer immunotherapy. The idea is to have a vaccine prompt the immune system to fight a tumor. Scientists at ETH Zurich have developed a method that allows them to determine which molecules are suited to patient-specific immunization.

Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective. In the face of this reality, researcher Prof. Dennis Wright has improved upon a new way to thwart the tricky pathogen, mycobacterium tuberculosis.